Amneal Pharmaceuticals, Inc.
A maker of generic and specialty medicines, Amneal Pharmaceuticals develops, manufactures and distributes hundreds of medications—from pills and injections to eye drops, creams and transdermal patches—that patients and pharmacies use every day. Founded in 2002 by brothers Chirag and Chintu Patel, the company grew from a bootstrapped family venture in New Jersey into one of the largest generic drugmakers in the United States. Fun fact: the name "Amneal" blends the founders' names, Amar and Neal.
This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D.
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.
This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D.
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Tushar Patel | 13D/AActivist | 17.6% | 61.34M | Aug 12, 2026 |
This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D. | ||||
| Chintu Patel | 13D/AActivist | 9.4% | 32.58M | Aug 12, 2026 |
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. | ||||
| Chirag Patel | 13D/AActivist | 8.4% | 29.10M | Aug 12, 2026 |
This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D. | ||||
| BlackRock, Inc. | 13GPassive | 7.6% | 24.12M | Apr 27, 2026 |
| Patel Dipan | 13D/AActivist | 5.4% | 16.90M | Mar 26, 2026 |
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42. | ||||
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Akram Mahesh | 13G/APassive | 6.56% | 20.56M | May 14, 2025 |
| UBS Group AG | 13G/APassive | — | — | Feb 10, 2025 |